WO1988007871A1 - Use of commercial lecithin as skin penetration enhancer - Google Patents

Use of commercial lecithin as skin penetration enhancer Download PDF

Info

Publication number
WO1988007871A1
WO1988007871A1 PCT/US1988/000886 US8800886W WO8807871A1 WO 1988007871 A1 WO1988007871 A1 WO 1988007871A1 US 8800886 W US8800886 W US 8800886W WO 8807871 A1 WO8807871 A1 WO 8807871A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
lecithin
process according
effective amount
skin
Prior art date
Application number
PCT/US1988/000886
Other languages
French (fr)
Inventor
Mahdi Fawzi
Uma R. Iyer
Majid Mahjour
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21895652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1988007871(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to AT88903109T priority Critical patent/ATE99960T1/en
Priority to DE3887156T priority patent/DE3887156T3/en
Priority to EP88903109A priority patent/EP0382716B2/en
Publication of WO1988007871A1 publication Critical patent/WO1988007871A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Lecithin as used in commerce, is the name given to a group of substances present in fats which are obtained mainly from oil seeds, for example, soybeans and rape seeds) and from egg yolks.
  • Commercial lecithin is a natural emulsifying agent used in foodstuffs and pharmaceutical products, for example, in creams, balms, or ointments.
  • Lecithin has also been described in dispersions or suspensions in propellants.
  • bronchodilators can be administered by inhalation means in a propellant containing lecithin.
  • an object of the present invention is a method of administering a drug transdermally or transmucosally by using lecithin in the pharmaceutical composition.
  • the present invention relates to a process for enhancing penetration of a drug through the skin and other biological membranes which comprises applying to the skin or membrane of a host in need thereof a pharmaceutical composition containing an active ingredient and an effective amount of lecithin.
  • Another aspect of the present invention is a pharmaceutical composition adapted for transdermal or transmucosal administration comprising an active ingredient and an effective amount of lecithin.
  • Transdermal pharmaceutical compositions are used as a means for avoiding the uncertainties of oral administration and the inconvenience of administration by rejection.
  • An active ingredient for purposes of the present invention is an effective amount of any therapeutically active drug.
  • Preferred drugs are those which find application in various therapeutic uses such as antihypertensives, analgesics, antitussives, antihistamines, bronchodilators, cognition activators, and others. Therefore, the lecithin compositions are expected to be useful in drugs such as procaterol, dextromethorphan, oxymorphone, diphenhydramine, and others.
  • the lecithin employed in the present invention is commercial lecithin or soy lecithin, for example, Lucas Meyer, Inc. commercial soy lecithins such as EpikuronTM 135F and CapcithinTM 50-R.
  • the amount of lecithin used in the transdermal formulations may vary depending on the amount of active ingredient needed and the use of other excipients.
  • a useful range of lecithin found to be effective for penetration enhancement is about 2 to about 40% by weight of the composition. Preferred is from about 5 to about 10%.
  • the present composition also may contain pharmaceutically acceptable excipients.
  • pharmaceutically acceptable excipients are, for example, tetraglycol (TG), alcohols, glycols, fatty acids, triacetin, silicon fluids, and the like.
  • TG tetraglycol
  • alcohols glycols
  • fatty acids fatty acids
  • triacetin silicon fluids
  • Table form illustrative of the present invention where the use of commercial soy lecithin was found to enhance penetration of various drugs through mouse skin.

Abstract

A method of enhancing penetration of a drug through the skin or other biological membranes using lecithin is herein described along with pharmaceutical compositions containing effective amounts of lecithin as a penetration enhancer.

Description

USE OF COMMERCIAL LEICITHIN AS SKIN PENETRATION ENHANCER
Background of the Invention
Lecithin, as used in commerce, is the name given to a group of substances present in fats which are obtained mainly from oil seeds, for example, soybeans and rape seeds) and from egg yolks. Commercial lecithin is a natural emulsifying agent used in foodstuffs and pharmaceutical products, for example, in creams, balms, or ointments.
Lecithin has also been described in dispersions or suspensions in propellants. For example, bronchodilators can be administered by inhalation means in a propellant containing lecithin.
It has now been found that lecithin enhances the penetration of a drug through the skin and across other biological membranes, such as intestinal, buccal, rectal, and. nasal. Thus an object of the present invention is a method of administering a drug transdermally or transmucosally by using lecithin in the pharmaceutical composition.
Summary of the Invention
Accordingly, the present invention relates to a process for enhancing penetration of a drug through the skin and other biological membranes which comprises applying to the skin or membrane of a host in need thereof a pharmaceutical composition containing an active ingredient and an effective amount of lecithin.
Another aspect of the present invention is a pharmaceutical composition adapted for transdermal or transmucosal administration comprising an active ingredient and an effective amount of lecithin.
Description of Preferred Embodiments Transdermal pharmaceutical compositions are used as a means for avoiding the uncertainties of oral administration and the inconvenience of administration by rejection. An active ingredient for purposes of the present invention is an effective amount of any therapeutically active drug.
Preferred drugs are those which find application in various therapeutic uses such as antihypertensives, analgesics, antitussives, antihistamines, bronchodilators, cognition activators, and others. Therefore, the lecithin compositions are expected to be useful in drugs such as procaterol, dextromethorphan, oxymorphone, diphenhydramine, and others.
The lecithin employed in the present invention is commercial lecithin or soy lecithin, for example, Lucas Meyer, Inc. commercial soy lecithins such as Epikuron™ 135F and Capcithin™ 50-R. The amount of lecithin used in the transdermal formulations may vary depending on the amount of active ingredient needed and the use of other excipients. A useful range of lecithin found to be effective for penetration enhancement is about 2 to about 40% by weight of the composition. Preferred is from about 5 to about 10%.
The present composition also may contain pharmaceutically acceptable excipients. These are, for example, tetraglycol (TG), alcohols, glycols, fatty acids, triacetin, silicon fluids, and the like. The following examples in table form are illustrative of the present invention where the use of commercial soy lecithin was found to enhance penetration of various drugs through mouse skin.
Figure imgf000005_0001

Claims

1. A process for enhancing penetration of a drug through the skin or other biological membranes which comprises administering to the skin or other membrane of a host in need thereof a pharmaceutical composition containing a therapeutically effective amount of an active ingredient and an effective amount of lecithin.
2. A process according to Claim 1, wherein the active ingredient is an antihypertensive.
3. A process according to Claim 1, wherein the active ingredient is an antihistamine.
4. A process according to Claim 1, wherein the active ingredient is an analgesic.
5. A process according to Claim 1, wherein the active ingredient is an antitussive.
6. A process according to Claim 1, wherein the active ingredient is an cognition activator.
7. A process according to Claim 1, wherein the active ingredient is a bronchodilator.
8. A process according to Claim 1, wherein the active ingredient is procaterol.
9. A process according to Claim 1, wherein the active ingredient is an diphenhydramine.
10. A process according to Claim 1, wherein the active ingredient is dextromethorphan.
11. A process according tc claim 1. wherein the active ingredient is oxymorphone.
12. A process according to Claim 1, wherein the effective amount of lecithin is 2 to 40%.
13. A process according to Claim 1, wherein the effective amount of lecithin is 5 to 10%.
14. A pharmaceutical composition adapted for transdermal or transmucosal administration comprising a therapeutically effective amount of an active ingredient, an effective amount of lecithin, and one or more pharmaceutically acceptable excipients.
15. A composition according to Claim 14, wherein the amount of lecithin is 2 to 40%.
16. A composition according to Claim 14, wherein the amount of lecithin is 5 to 1 0%.
17. A composition according to Claim 14, wherein the active ingredient is diphenhydramine.
18. A composition according to Claim 14, wherein the active ingredient is dextromethorphan.
19. A composition according to Claim 14, wherein the active ingredient is oxymorphone.
20. A composition according to Claim 14, wherein procaterol is the active ingredient.
PCT/US1988/000886 1987-04-13 1988-03-18 Use of commercial lecithin as skin penetration enhancer WO1988007871A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT88903109T ATE99960T1 (en) 1987-04-13 1988-03-18 USE OF COMMERCIAL LECITHIN AS A SKIN PENETRATION ENHANCER.
DE3887156T DE3887156T3 (en) 1987-04-13 1988-03-18 USE OF COMMERCIAL LECITHIN AS A SKIN PENETRATION CONVEYOR.
EP88903109A EP0382716B2 (en) 1987-04-13 1988-03-18 Use of commercial lecithin as skin penetration enhancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US037,671 1987-04-13
US07/037,671 US4783450A (en) 1987-04-13 1987-04-13 Use of commercial lecithin as skin penetration enhancer

Publications (1)

Publication Number Publication Date
WO1988007871A1 true WO1988007871A1 (en) 1988-10-20

Family

ID=21895652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/000886 WO1988007871A1 (en) 1987-04-13 1988-03-18 Use of commercial lecithin as skin penetration enhancer

Country Status (5)

Country Link
US (1) US4783450A (en)
EP (1) EP0382716B2 (en)
JP (1) JP2714413B2 (en)
DE (1) DE3887156T3 (en)
WO (1) WO1988007871A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011767A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company Transdermal delivery of (e)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-o-methyloxine hcl and related compounds in the treatment of cognitive disorders and for analgesia
WO1993015719A1 (en) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal itraconazole formulations
WO1993015718A1 (en) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal piroxicam formulations
US5505960A (en) * 1992-02-12 1996-04-09 Janssen Farmaceutici S.P.A. Liposomal piroxicam formulations
WO1997039742A1 (en) * 1996-04-23 1997-10-30 Pharmacia & Upjohn Ab Transdermally administered dextromethorphan as antitussive agent
WO1999029301A2 (en) * 1997-12-08 1999-06-17 Phares Pharmaceutical Research N.V. Lipid compositions and their use
DE10024413A1 (en) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmaceutical and / or cosmetic preparation

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981681A (en) * 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5498607A (en) * 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
TW224048B (en) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
EP0721348B1 (en) * 1993-09-29 1999-09-01 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
WO1997002041A1 (en) 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
WO2000038653A1 (en) 1998-12-23 2000-07-06 Idea Ag. Improved formulation for topical non-invasive application in vivo
PT1031346E (en) 1999-01-27 2002-09-30 Idea Ag NOT INVASIVE VACCINATION THROUGH SKIN
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ES2283425T3 (en) * 2000-08-03 2007-11-01 Antares Pharma Ipl Ag NEW COMPOSITION FOR THE TRANSDERMAL AND / OR TRANSMUCTIVE ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURE ADEQUATE THERAPEUTIC LEVELS.
PT1372708E (en) 2001-02-13 2008-09-29 Us Gov Sec Army Vaccine for transcutaneous immunization against travellers` diarrhoea
RU2286801C2 (en) 2001-05-01 2006-11-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Water-absorbing biphase bioadhesive compositions
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
MXPA04011808A (en) * 2002-05-31 2005-09-12 Univ Mississippi Transmucosal delivery of cannabinoids.
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
CN102764247B (en) 2004-01-30 2016-04-20 考里安国际公司 The rapidly dissolving film of active agent delivery
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
AU2005244096B2 (en) 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US20090028806A1 (en) * 2005-02-25 2009-01-29 Shigeo Suzuki Medicine for External Application Containing Anti-Inflammatory Agent and Soy Lecithin
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
WO2009092040A2 (en) * 2008-01-17 2009-07-23 Gary Dean Bennett Topical pain formulation
WO2009110205A1 (en) 2008-03-04 2009-09-11 ナガセケムテックス株式会社 Agent for increasing the quantity of hyaluronic acid
EP2271349B1 (en) 2008-04-01 2017-03-15 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
EP2265125B1 (en) 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
EP2296686B2 (en) 2008-05-21 2017-11-01 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
EP2376633A1 (en) 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
JP5674684B2 (en) 2009-02-03 2015-02-25 マイクロビオン コーポレーション Bismuth-thiol as a disinfectant for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
US20140065209A1 (en) 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
EP2726080A1 (en) 2011-06-29 2014-05-07 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
DK2897620T3 (en) 2012-09-21 2020-08-17 Intensity Therapeutics Inc CANCER TREATMENT PROCEDURE
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CA2919194A1 (en) 2013-07-23 2015-01-29 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
JP2016525548A (en) 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉ� Methods and compositions comprising desmopressin in combination with Β-3 adrenergic receptor stimulants
SI3546461T1 (en) 2013-11-15 2021-11-30 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
US20150182451A1 (en) * 2013-12-27 2015-07-02 The Dial Corporation Cleansing composition for hormone deposition
KR20230048175A (en) 2014-08-15 2023-04-10 더 존스 홉킨스 유니버시티 Composite material for tissue restoration
WO2016081772A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
AU2016211243B2 (en) 2015-01-30 2020-09-10 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
WO2016186157A1 (en) * 2015-05-19 2016-11-24 株式会社メドレックス Transdermal liquid preparation
US20190060516A1 (en) 2015-08-17 2019-02-28 The Johns Hopkins University In situ forming composite material for tissue restoration
MA43879A (en) 2016-01-29 2018-12-05 Oncoceutics Inc MODULATION OF G-PROTECTED RECEPTORS (GPCR) BY IMIPRIDONES
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
WO2019217767A1 (en) 2018-05-09 2019-11-14 The Johns Hopkins University Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
EP3790602A1 (en) 2018-05-09 2021-03-17 The Johns Hopkins University Nanofiber-hydrogel composites for cell and tissue delivery
EP3863622A1 (en) 2018-10-09 2021-08-18 University Of Rochester Treatment of vulvovaginal disorders
US20220000818A1 (en) 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
AU2021376539A1 (en) * 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210759A2 (en) * 1985-06-28 1987-02-04 R.P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2001334B (en) * 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
FR2478485A1 (en) * 1980-03-24 1981-09-25 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITIONS IN THE FORM OF STABLE EMULSIONS OF THE OIL-IN-WATER TYPE
JPS62123132A (en) * 1985-11-21 1987-06-04 Michio Nakanishi Composition for remedying bronchial asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210759A2 (en) * 1985-06-28 1987-02-04 R.P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 106, no. 14, 6 April 1987 (Columbus, Ohio, US), see page 373, abstract no. 107916n, & JP-A-61225122 (EISAI CO., LTD) 6 October 1986 *
Chemical Abstracts, vol. 108, no. 12, 21 March 1988 (Columbus, Ohio, US), see page 447, abstract no. 10143t, & JP-A-62123132 (M. NAKANASHI) 4 June 1987 *
Patent Abstracts of Japan, vol. 8, no. 150, (C-233)(1587), 12 July 1984; & JP-A-5955819 (NITTO DENKI KOGYO K.K.) 31 March 1984 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011767A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company Transdermal delivery of (e)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-o-methyloxine hcl and related compounds in the treatment of cognitive disorders and for analgesia
WO1993015719A1 (en) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal itraconazole formulations
WO1993015718A1 (en) * 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal piroxicam formulations
US5505960A (en) * 1992-02-12 1996-04-09 Janssen Farmaceutici S.P.A. Liposomal piroxicam formulations
WO1997039742A1 (en) * 1996-04-23 1997-10-30 Pharmacia & Upjohn Ab Transdermally administered dextromethorphan as antitussive agent
US6335030B1 (en) 1996-04-23 2002-01-01 Pharmacia & Upjohn Ab Transdermally administered dextromethorphan as antitussive agent
WO1999029301A2 (en) * 1997-12-08 1999-06-17 Phares Pharmaceutical Research N.V. Lipid compositions and their use
WO1999029301A3 (en) * 1997-12-08 1999-07-22 Phares Pharm Res Nv Lipid compositions and their use
DE10024413A1 (en) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmaceutical and / or cosmetic preparation

Also Published As

Publication number Publication date
EP0382716B1 (en) 1994-01-12
US4783450A (en) 1988-11-08
JP2714413B2 (en) 1998-02-16
DE3887156T2 (en) 1994-04-28
DE3887156T3 (en) 1998-04-16
EP0382716A1 (en) 1990-08-22
DE3887156D1 (en) 1994-02-24
EP0382716B2 (en) 1998-01-28
JPH02502994A (en) 1990-09-20

Similar Documents

Publication Publication Date Title
EP0382716B1 (en) Use of commercial lecithin as skin penetration enhancer
EP0261429B1 (en) Penetration enhancement systems and the preparation thereof
CA2146637C (en) Pharmaceutical compositions and methods for treating cold symptoms
EP2373346B1 (en) Ibuprofen for topical administration
RU99114830A (en) THERAPEUTIC MEANS
KR20050120753A (en) Transmucosal drug delivery system
JP2006518761A5 (en)
JP3487633B2 (en) Skin disease treatment emulsion
US8003696B2 (en) Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain
JPH02503672A (en) Fatty acids and their short chain esters as penetration enhancers in aqueous systems
AU4044589A (en) Novel method of administering aspirin and dosage forms containing same
CA2169172A1 (en) Percutaneously absorbable preparation
JPH069381A (en) Soft capsule containing ibuprofen
JP5161472B2 (en) Analgesic composition
EP0438147A2 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
JP3496158B2 (en) Gelatin capsule preparation containing tranexamic acid
US5401728A (en) Lecithin based topical liniment
JPS61280435A (en) Lymph orienting preparation of cyclosporin
AR002727A1 (en) THE USE OF RIDOGREL FOR THE MANUFACTURE OF A MEDICATION USEFUL FOR THE TREATMENT OF DIGESTIVE INFLAMMATORY DISEASES, A PHARMACEUTICAL COMPOSITION INCLUDING RIDOGREL AND A PROCEDURE FOR PREPARING SUCH COMPOSITION.
JPS6092214A (en) Composition for filling soft capsule
EP0238198A3 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
JP3277735B2 (en) Composition for promoting absorption of naphthoic acid derivative
JP3427445B2 (en) Cream
JP4710240B2 (en) Pharmaceutical composition
JP2005289906A (en) Medicinal composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988903109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988903109

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1988903109

Country of ref document: EP